December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Rahul Banerjee: Safety run-in for Teclistamab and Lenalidomide maintenance after ASCT
Dec 10, 2024, 13:59

Rahul Banerjee: Safety run-in for Teclistamab and Lenalidomide maintenance after ASCT

Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center, shared a post on X:

“MajesTEC-4! Zamagni et al: Safety run-in for tec + len maintenance after ASCT.

First time we’re seeing bsAb maintenance data in Multiple Myeloma Bottom line: it works!

But important to see: Tec as maintenance is same as tec in RRMM: CRS and infections can happen. Use IVIG!”

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Authors: Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk

Rahul Banerjee: Safety run-in for Teclistamab and Lenalidomide maintenance after ASCT

Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency at the University of Pennsylvania health system.

He completed his fellowship in haematology and oncology from the University of California, San Francisco. He has authored over 70 peer-reviewed publications. His clinical interests include multiple myeloma.

Highlights from Day 1 of ASH24